<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="48492">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02474927</url>
  </required_header>
  <id_info>
    <org_study_id>PRO15010152</org_study_id>
    <nct_id>NCT02474927</nct_id>
  </id_info>
  <brief_title>Combination Therapy With Carfilzomib for the Antibody-Mediated Rejection Diagnosis in Lung Transplantation</brief_title>
  <official_title>Combination Therapy With the Proteasome Inhibitor Carfilzomib for the Antibody-Mediated Rejection Diagnosis in Lung Transplantation Trial (PICARD-Lung)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>John F. McDyer, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The clinical trial is a Phase II open label, single-arm pilot study to evaluate the safety
      and efficacy of combination therapy with carfilzomib, plasma exchange and intravenous
      immunoglobulins for AMR after lung transplantation and elucidate important clinical and
      immunologic phenotypes and mechanisms associated with these outcomes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main objective of the proposed clinical investigation is to evaluate the effects of
      carfilzomib in addition to conventional therapy on short-term outcomes after the diagnosis
      of antibody-mediated rejection in lung transplant recipients. In this study, Carfilzomib
      will be administered at a dose of 20 mg/m2 on two consecutive days, each week for three
      weeks (Days 1 2, 8, 9, 15, and 16) to constitute one therapeutic cycle. Carfilzomib may be
      administered for 1-2 complete cycles in the study. Patients will be followed for the
      duration of their hospital admission after enrollment. Post treatment follow-up will also
      occur on Days 42 and 90.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Absolute change in DSA strength, titer, and complement fixation</measure>
    <time_frame>Day 1 to Day 42</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Absolute change in DSA strength, titer, and complement fixation</measure>
    <time_frame>Day 1 to Day 90 and Day 42 to Day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute change in forced expiratory volume in 1 second (FEV1)</measure>
    <time_frame>Day 1 to Day 42 and to Day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence or absence of pathologic changes consistent with AMR on transbronchial biopsy</measure>
    <time_frame>Day 1 to Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient death attributable to AMR</measure>
    <time_frame>Day 1 to Day 90</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Non-lung irreversible end-organ failure</measure>
    <time_frame>Day 1 to Day 16</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of adverse effects (AE)</measure>
    <time_frame>Day 1 to Day 16</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of adverse effects (AE) requiring dose-modification</measure>
    <time_frame>Day 1 to Day 16</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of hypogammaglobulinemia</measure>
    <time_frame>Day 1 to Day 16</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of culture-proven de novo infection</measure>
    <time_frame>Day 1 to Day 42</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Diagnosis of systemic inflammatory response syndrome</measure>
    <time_frame>Day 1 to Day 16</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Patient death</measure>
    <time_frame>Day 1 to Day 90</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Lung Transplant Rejection</condition>
  <arm_group>
    <arm_group_label>Carfilzomib Treatment Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Carfilzomib will be administered at a dose of 20 mg/m2 on two consecutive days, each week for three weeks (Days 1 2, 8, 9, 15, and 16) to constitute one therapeutic cycle. Carfilzomib may be administered for 1-2 complete cycles in the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carfilzomib</intervention_name>
    <description>Carfilzomib will be used in combination with the conventional therapy (plasma exchange and intravenous immunoglobulins)</description>
    <arm_group_label>Carfilzomib Treatment Arm</arm_group_label>
    <other_name>Kyprolis</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult lung transplant recipients â‰¥ 18 years of age who meet the diagnostic criteria
             for AMR and who have underwent PFT testing unless intubated and transbronchial biopsy
             prior to enrollment.

        Exclusion Criteria:

          -  Direct contraindications or previous intolerances to any component of the standard of
             care regimen including PLEX, 5% human albumin, 5% gammagard S/D or 10% gammagard
             liquid

          -  Leukopenia

          -  Neutropenia

          -  Thrombocytopenia

          -  Known Child-Pugh B/C cirrhosis

          -  Total bilirubin &gt; 4

          -  ALT &gt; 90

          -  Known systolic heart failure with LVEF &lt; 40%

          -  Known pulmonary hypertension

          -  Any uncontrolled comorbid condition

          -  Pregnant women

          -  Breastfeeding women

          -  Ongoing bacterial or fungal or viral infection that is life-threatening

          -  Active cytomegalovirus disease

          -  Active varicella zoster infection

          -  Previous intolerance to carfilzomib

          -  Concurrent use of another proteasome inhibitor (e.g., bortezomib)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John McDyer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chrisitine Sanserino, BSN, RN</last_name>
    <phone>412-692-2263</phone>
    <email>cns47@pitt.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Swati Gulati, MS</last_name>
    <email>gulatis2@upmc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 3, 2017</lastchanged_date>
  <firstreceived_date>May 21, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>John F. McDyer, MD</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>antibody-mediated rejection</keyword>
  <keyword>lung transplant</keyword>
  <keyword>Carfilzomib</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Proteasome Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
